atombp.us valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-Agent: * | ||
Meta Tags
| Title | Home New - Atom |
| Description | Latest News from Atom Home About Atom Management Team Advisory Board Investors Our Programs Pipeline Gout & Hyperuricemia NASH News & Events Contact Us Providing Patients with |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 198.71.233.202 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
atombp.us Valuation
|
US$293,648
Last updated: 2023-05-17 13:31:14
atombp.us has Semrush global rank of 36,044,186. atombp.us has an estimated worth of US$ 293,648, based on its estimated Ads revenue. atombp.us receives approximately 33,883 unique visitors each day. Its web server is located in United States, with IP address 198.71.233.202. According to SiteAdvisor, atombp.us is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$293,648 |
| Daily Ads Revenue | US$272 |
| Monthly Ads Revenue | US$8,132 |
| Yearly Ads Revenue | US$97,582 |
| Daily Unique Visitors | 2,259 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| atombp.us. | A | 600 | IP: 198.71.233.202 |
| atombp.us. | NS | 3600 | NS Record: ns75.domaincontrol.com. |
| atombp.us. | NS | 3600 | NS Record: ns76.domaincontrol.com. |
HtmlToTextCheckTime:2023-05-17 13:31:14
| Home About Atom Management Team Advisory Board Investors Our Programs Pipeline Gout & Hyperuricemia NASH News & Events Contact Us Providing Patients with Effective, Safe, and Convenient Medicines Learn More About Atom Focused on Oral Drugs for Worldwide Inflammatory and Metabolic Diseases Learn About Our Pipeline Creating Best-In-Class Molecules for Unmet Medical Needs Read Our Latest News Learn how and why Atom Bioscience is developing a new treatment for gout — and the impact it may have on millions of lives. Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout and non-alcoholic steatohepatitis (NASH) for which there are no effective treatments. Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is |